{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:14:35Z","timestamp":1784308475306,"version":"3.55.0"},"reference-count":87,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:p>As outcomes for low-risk breast cancer continue to improve, research and clinical paradigms are increasingly focused on appropriate deintensification with the goal of improving the therapeutic ratio of breast cancer treatment. These deintensification approaches span across disciplines including breast surgery, radiation therapy, and systemic therapy. With regard to breast surgery, studies have continued to push deintensification when it comes to surgical margins with breast conservation, reducing re-excision rates, whereas deintensification of axillary surgery has reduced the rates of axillary lymph node dissection and increasingly the need for any axillary surgery, including sentinel lymph node biopsy for low-risk patients. With regard to radiation therapy, studies have allowed for a drastic reduction in treatment duration, whereas approaches that reduce the target of treatment have led to a change from from treatment daily for 5-7 weeks to many low-risk patients completing treatment in just five treatments. With regard to systemic therapy, use of genomic assays and tumor biology has led to reduced utilization of cytotoxic chemotherapy, with studies also allowing for dose reduction of endocrine therapy for patients with ductal carcinoma in situ. Moving forward, greater focus should be placed on interdisciplinary deintensification approaches such as the consideration of radiation therapy alone as compared with endocrine therapy alone for low-risk breast cancers.<\/jats:p>","DOI":"10.1200\/op-24-00538","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T19:59:08Z","timestamp":1729022348000},"page":"323-332","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":6,"title":["Reimagining Deintensification for Low-Risk Breast Cancer"],"prefix":"10.1200","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1305-8431","authenticated-orcid":true,"given":"Chirag","family":"Shah","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0536-9005","authenticated-orcid":true,"given":"Megan","family":"Kruse","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahraa","family":"Al-Hilli","sequence":"additional","affiliation":[{"name":"Breast Center, Integrated Surgical Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022152"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199306033282202"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61629-2"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-14902-z"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-13592-3"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08878-9"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.07.043"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.3935"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5446-2"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.3573"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4916-2"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.05.043"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21535"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70207-2"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.11470"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.5838"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01565"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313487"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.3759"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-5932-1"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.10986"},{"key":"e_1_3_5_23_2","unstructured":"Comparison of axillary lymph node dissection with axillary radiation for patients with node-positive breast cancer treated with chemotherapy. https:\/\/clinicaltrials.gov\/study\/NCT01901094"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00635"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.11.026"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906260"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70386-3"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02750"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30932-6"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2018.01.012"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.07.2320"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00650"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32514-0"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31145-5"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32515-2"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.11.006"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00018-9"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2023.11.001"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2022.07.004"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/tbj.13875"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-200006000-00013"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.12.028"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09356-y"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2013.10.005"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.2615"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2207586"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.02.031"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.101"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2008.06.027"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02289"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02270"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302344"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02476-5"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.04.037"},{"key":"e_1_3_5_55_2","unstructured":"De-escalation of breast radiation trial for hormone sensitive HER-2 negative oncotype recurrence score less than or equal to 18 breast cancer (DEBRA). https:\/\/clinicaltrials.gov\/study\/NCT04852887"},{"key":"e_1_3_5_56_2","unstructured":"Regional radiotherapy in biomarker low-risk node positive and T3N0 breast cancer (TAILOR RT). https:\/\/clinicaltrials.gov\/study\/NCT03488693"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1415340"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01082-6"},{"key":"e_1_3_5_59_2","doi-asserted-by":"crossref","unstructured":"Mamounas EP Bandos H White JR et al: Loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: Primary outcomes of NRG Oncology\/NSABP B-51\/RTOG 1304. San Antonio Breast Cancer Symposium 2023","DOI":"10.1158\/1538-7445.SABCS23-GS02-07"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgq039"},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8588"},{"key":"e_1_3_5_62_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2813-6"},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01083"},{"key":"e_1_3_5_64_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13236103"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.06.072"},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.07.414"},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-15566-5"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt067"},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw256"},{"key":"e_1_3_5_70_2","unstructured":"Comparing an operation to monitoring with or without endocrine therapy (COMET) trial for low risk DCIS. https:\/\/clinicaltrials.gov\/study\/NCT02926911"},{"key":"e_1_3_5_71_2","unstructured":"National Comprehensive Cancer Network: Breast guidelines 4.2024"},{"key":"e_1_3_5_72_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510764"},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602253"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804710"},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108873"},{"key":"e_1_3_5_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00051-7"},{"key":"e_1_3_5_77_2","unstructured":"Tarantino P Tayob N Villacampa G et al: Adjuvant trastuzumab emtansine versus paclitaxel plus trastuzumab for stage I human epidermal growth factor receptor 2 positive breast cancer: 5 year results and correlative analyses from ATEMPT. J Clin Oncol 42:3652-3665 2024"},{"key":"e_1_3_5_78_2","unstructured":"Testing the effect of decreasing chemotherapy in patients with HER2-positive breast cancer without evidence of remaining cancer after receiving pre-surgery chemotherapy and HER2-targeted therapy. https:\/\/ecog-acrin.org\/clinical-trials\/ea1181-compassher2-pcr-breast-cancer\/"},{"key":"e_1_3_5_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00054-0"},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11423-4"},{"key":"e_1_3_5_81_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-018-0553-y"},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01129-0"},{"key":"e_1_3_5_83_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02900"},{"key":"e_1_3_5_84_2","unstructured":"Adjuvant endocrine therapy for low risk breast cancer (LALEAST). https:\/\/clinicaltrials.gov\/study\/NCT03917082"},{"key":"e_1_3_5_85_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS615"},{"key":"e_1_3_5_86_2","unstructured":"Exclusive endocrine therapy or radiation therapy for women aged \u226570 years early stage breast cancer (EUROPA). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04134598"},{"key":"e_1_3_5_87_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05706-2"},{"key":"e_1_3_5_88_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00992"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-24-00538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T22:00:25Z","timestamp":1741903225000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-24-00538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1200\/OP-24-00538"],"URL":"https:\/\/doi.org\/10.1200\/op-24-00538","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2024-07-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}